Novel larvicide tablets of Bacillus thuringiensis var. israelensis: Assessment of larvicidal effect on Aedes aegypti (Diptera: Culicidae) in Colombia.
Aedes (Stegomyia) aegypti is the vector for dengue, chikungunya, and Zika arboviruses. Bti-CECIF is a bioinsecticide designed and developed in the form of a solid tablet for the control of this vector. It contains Bacillus thuringiensis var. israelensis (Bti) serotype H-14. To evaluate under semi-field and field conditions the efficacy and residual activity of Bti-CECIF tablets on Aedes aegypti larvae in two Colombian municipalities. We tested under semi-field conditions in plastic tanks (Rotoplast™) four different Bti doses (0.13, 0.40, 0.66 and 0.93 mg/L) in the municipality of Apartadó, department of Antioquia, to assess Bti-CECIF efficacy (percentage of reduction of larval density) and the residual activity in water tanks containing A. aegypti third-instar larvae. The efficacy and residuality of the most lethal dose were subsequently evaluated under field conditions in cement tanks in the municipality of San Carlos, department of Córdoba. Under semi-field conditions, the highest tested dose exhibited the greatest residual activity (15 days) after which larval mortality was 80%. Under field conditions, the highest tested Bti-CECIF doses showed 100% mortality and exhibited a residual activity of seven days in 90% of the tanks. Bti-CECIF tablets effectively controlled A. aegypti larvae under field conditions for up to seven days post-treatment.